Literature DB >> 23899460

Complex interaction between anandamide and the nitrergic system in the dorsolateral periaqueductal gray to modulate anxiety-like behavior in rats.

S F Lisboa1, A C Magesto2, J C Aguiar2, L B M Resstel2, F S Guimarães2.   

Abstract

Stimulation of cannabinoid CB1 receptors or inhibition of nitric oxide synthase (NOS) in the dorsolateral periaqueductal gray (dlPAG) decreases anxiety-like behavior. Moreover, activation of CB1 receptors attenuates flight responses induced by nitric oxide (NO) donors in the dlPAG, suggesting that endocannabinoids and NO could interact to control defensive responses such as anxiety-like behavior. To test this hypothesis male Wistar rats received intra-dlPAG microinjections of anandamide (AEA) or NO inhibitors and were tested in the elevated plus maze (EPM). Combined administration of low and ineffective doses of AEA and the NO scavenger (c-Ptio), the nNOS inhibitor (NPA) or the soluble guanylate cyclase inhibitor (ODQ) induced anxiolytic-like effects. The CB1 receptor antagonist AM251, but not the GABAA receptor antagonist bicuculline, attenuated the effect induced by AEA+c-Ptio combination. No effect, however, was found when anxiolytic doses of these same drugs were administered together. Combination of higher, ineffective doses of AEA and c-Ptio, NPA or ODQ was again anxiolytic. The effect of the former combination was prevented by low and ineffective doses of the GABAA receptor antagonist bicuculline or the GABA synthesis inhibitor L-allilglycine, suggesting that they depend on GABAA-mediated neurotransmission. AM251 was also able to attenuate this effect, indicating that in the presence of NO inhibition, the resultant anxiolytic-like effect could be due to AEA action on CB1 receptors. The present results suggest that the AEA and nitrergic systems exert a complex functional interaction in the dlPAG to modulate anxiety behavior, probably interfering, in addition to glutamate, also with GABAergic mechanisms.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anandamide; Anxiety; GABA; Glutamate; Nitric oxide; Periaqueductal gray

Mesh:

Substances:

Year:  2013        PMID: 23899460     DOI: 10.1016/j.neuropharm.2013.07.008

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  3 in total

1.  Increased Contextual Fear Conditioning in iNOS Knockout Mice: Additional Evidence for the Involvement of Nitric Oxide in Stress-Related Disorders and Contribution of the Endocannabinoid System.

Authors:  Sabrina F Lisboa; Felipe V Gomes; Andréia L Silva; Daniela L Uliana; Laura H A Camargo; Francisco S Guimarães; Fernando Q Cunha; Sâmia R L Joca; Leonardo B M Resstel
Journal:  Int J Neuropsychopharmacol       Date:  2015-01-24       Impact factor: 5.176

2.  A network pharmacology approach to predict potential targets and mechanisms of "Ramulus Cinnamomi (cassiae) - Paeonia lactiflora" herb pair in the treatment of chronic pain with comorbid anxiety and depression.

Authors:  Hao-Tian Pan; Zi-Qi Xi; Xu-Qiang Wei; Ke Wang
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709

3.  Inducible Nitric Oxide Synthase Inhibition in the Medial Prefrontal Cortex Attenuates the Anxiogenic-Like Effect of Acute Restraint Stress via CB1 Receptors.

Authors:  Arthur A Coelho; Carla Vila-Verde; Ariandra G Sartim; Daniela L Uliana; Laura A Braga; Francisco S Guimarães; Sabrina F Lisboa
Journal:  Front Psychiatry       Date:  2022-07-14       Impact factor: 5.435

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.